Safety and Effectiveness of Metabolic and Bariatric Procedures in Heart Failure: A Multicenter Retrospective Cohort Study
Obesity · 2026-05 · 34 (5) · 1151-1162
DOI: 10.1002/oby.70173 ↗At a glance
Multizentrische Studie in Obesity, published online on 2026-03-19. Written by John W Ostrominski and 6 co-authors. Institution: Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Major MEDLINE topics: Heart Failure, Bariatric Surgery, Obesity. Cited 1 times so far (Crossref); 45 references. Funded by: NIH HHS, Apollo Endosurgery, Boston Scientific, Cook Medical, Fractyl, GI Dynamics, and USGI Medical, Novo Nordisk.
Topics: Herzinsuffizienz
Abstract (original language)
Objective
This study examined the safety and effectiveness of metabolic and bariatric procedures (MBPs), including surgical and endoscopic interventions, among individuals with versus without heart failure (HF).
Methods
This multicenter retrospective cohort study (2021–2023) identified persons with HF who underwent MBPs at two medical centers. Thirty‐day safety events and changes in body weight and medication use were assessed.
Results
Of 1678 MBPs, 41 (2.4%) were performed in adults with HF (mean age, 51 ± 15 years; 66% female; mean BMI, 44 ± 7 kg/m 2 ). Despite older age and more obesity‐related complications, persons with HF did not appear to experience a higher risk of any safety event at 30 days versus those without HF (24% vs. 16%; adjusted OR, 1.64; 95% CI, 0.76–3.58; p = 0.21). Thirty‐day change in body weight was similar between those with (−5.9%; 95% CI, −6.9%, −4.9%) and without HF (−6.2%; 95% CI, −6.4%, −6.0%; p comparison = 0.57). By 1 year, individuals with HF experienced significant reductions in body weight (mean change, −18.7%; 95% CI, −22.1%, −15.3%; p < 0.001), cardiovascular ( p = 0.003) and glucose‐lowering medications ( p < 0.001), and loop diuretics ( p = 0.003).
Conclusions
These findings suggest that MBPs are safe and effective in well‐selected adults with obesity and HF. However, larger and prospective studies are warranted to enhance understanding of MBP risk/benefit in this population. image
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Laboratory for Surgical and Metabolic Research, Division of General and Gastrointestinal Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
ORCID profiles: Madeleine Schwede
Funding
- NIH HHS
- Apollo Endosurgery, Boston Scientific, Cook Medical, Fractyl, GI Dynamics, and USGI Medical
- Novo Nordisk
- Novartis
- scPharmaceuticals
- American Heart Association
- AstraZeneca
- National Institutes of Health
Cite
APA
Ostrominski, J. W., Schwede, M., Lodi, J., Jirapinyo, P., Spector, D., Sheu, E. G., & Platz, E. (2026). Safety and Effectiveness of Metabolic and Bariatric Procedures in Heart Failure: A Multicenter Retrospective Cohort Study. Obesity, 34(5), 1151-1162. https://doi.org/10.1002/oby.70173
Vancouver
Ostrominski JW, Schwede M, Lodi J, Jirapinyo P, Spector D, Sheu EG, et al. Safety and Effectiveness of Metabolic and Bariatric Procedures in Heart Failure: A Multicenter Retrospective Cohort Study. Obesity. 2026;34(5):1151-1162. doi:10.1002/oby.70173
BibTeX
@article{Ostrominski2026,
author = {Ostrominski, John W and Schwede, Madeleine and Lodi, Jenna and Jirapinyo, Pichamol and Spector, David and Sheu, Eric G and Platz, Elke},
title = {Safety and Effectiveness of Metabolic and Bariatric Procedures in Heart Failure: A Multicenter Retrospective Cohort Study},
journal = {Obesity},
year = {2026},
volume = {34},
number = {5},
pages = {1151--1162},
doi = {10.1002/oby.70173}
}
EUVIMED